Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered this past year (virtually) to review information presented at ASCO and ESMO 2021, regarding patients dealing with a Lung Cancer diagnosis.
For this series, the doctors discuss new trials for patients with NSCLC and SCLC. The video discussions cover the following topics:
- IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung Cancer
- Surgical Outcomes and Checkmate 816: Addition of Nivolumab in Early Stage Non-Small Cell Lung Cancer
- FDA Analysis of Immunotherapy With or Without Chemo in Advanced NSCLC and Low PDL-1
- Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone
- Carbo/Pemetrexed/Pembro and Acquired Resistance in EGFRm+ or ALK+ NSCLC
- Immune Therapy for Brain Metastases
- CodeBreak 100: Sotorasib in KRAS G12C Mutation
- Amivantamab and Mobocertinib for EGFR Exon 20
- Amivantamab + Lazertinib in EGFR Mutation, Patritumab Deruxtecan in EGFR Mutation-Positive Acquired Resistance
- MYLUNG Consortium: Overall Biomarker Testing
- Lurbinectedin in Small Cell Lung Cancer and the Failed Atlantis Trial
- Circulatory Tumor DNA
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…